Stockscreener 앱 받기
66.39
2.04%
1.33
시간 외 거래:
66.60
0.21
+0.32%
전일 마감가:
$65.06
열려 있는:
$64
하루 거래량:
1.54M
Relative Volume:
0.66
시가총액:
$12.69B
수익:
$217.77M
순이익/손실:
$-438.86M
주가수익비율:
-27.55
EPS:
-2.41
순현금흐름:
$-456.33M
1주 성능:
+7.43%
1개월 성능:
+17.50%
6개월 성능:
+97.24%
1년 성능:
+175.36%
1일 변동 폭
$63.91
$67.71
1주일 범위
$62.06
$67.93
52주 변동 폭
$21.72
$69.48
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
BBIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
66.39 | 12.54B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.15 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
693.50 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.16 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
907.98 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.22 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
(BBIO) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
What moving averages say about BridgeBio Pharma Inc.Market Growth Report & Fast Gain Stock Tips - newser.com
How dovish Fed policy supports BridgeBio Pharma Inc. (2CL) stock2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Why BridgeBio Pharma Inc. (2CL) stock stays resilientWeekly Investment Recap & Weekly Watchlist of Top Performers - newser.com
What drives BridgeBio Pharma Inc stock priceDividend Aristocrats List & Fast Growing Portfolio Trading - earlytimes.in
What indicators show strength in BridgeBio Pharma Inc.2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com
How BridgeBio Pharma Inc. stock performs in stagflationWeekly Risk Report & Consistent Income Trade Recommendations - newser.com
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Wave Life Sciences (WVE) and BridgeBio Pharma (BBIO) - The Globe and Mail
BridgeBio Pharma (BBIO): Exploring Valuation After a 20% Share Price Surge - Yahoo Finance
Wells Fargo Maintains BridgeBio Pharma (BBIO) Overweight Recommendation - Nasdaq
BridgeBio Pharma (BBIO): Wells Fargo Raises Price Target to $84 - GuruFocus
BridgeBio Pharma CEO Kumar Neil sells $5m in shares By Investing.com - Investing.com Australia
BridgeBio Pharma CEO Kumar Neil sells $5m in shares - Investing.com
Bridgebio Pharma Insider Sold Shares Worth $4,983,111, According to a Recent SEC Filing - MarketScreener
Pfizer’s Advertising Challenge Against BridgeBio’s Attruby Leverages US FDA Untitled Letter - Citeline News & Insights
Sustained drop in all-cause mortality observed with BridgeBio’s acoramidis - The Pharma Letter
BridgeBio Pharma Insider Sold Shares Worth $3,888,999, According to a Recent SEC Filing - MarketScreener
Can machine learning forecast BridgeBio Pharma Inc. recoveryTrade Risk Assessment & Low Risk High Reward Ideas - newser.com
Analyzing BridgeBio Pharma Inc. with risk reward ratio chartsTrade Risk Assessment & AI Powered Market Entry Ideas - newser.com
BridgeBio Pharma’s Global Expansion Shockwave: Why Investors Are Buzzing! - Smartkarma
BridgeBio (BBIO) Reports Promising Data for Acoramidis in Cardia - GuruFocus
BridgeBio presents data from ATTRibute-CM study on acoramidis - TipRanks
BridgeBio Pharma Reports Significant All-Cause Mortality Reductions with Acoramidis in Variant ATTR-CM Patients at AHA Scientific Sessions 2025 - Quiver Quantitative
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - GlobeNewswire
Using Bollinger Bands to evaluate BridgeBio Pharma Inc.2025 Earnings Surprises & Entry Point Strategy Guides - newser.com
JP Morgan Raises Price Target for BBIO, Maintains Overweight Rat - GuruFocus
BridgeBio Pharma Director Makes a Multi-Million Dollar Stock Move! - TipRanks
BridgeBio Pharma Director Ronald J Daniels Sells Over $3.8 Million in Company Stock - TradingView
Long term debt to total equity ratio of BridgeBio Pharma, Inc. – HAM:2CL - TradingView
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity - Stock Titan
National Advertising Division Will Refer BridgeBio Pharma to Government Agencies for Failure to Participate in Inquiry - The Manila Times
Will BridgeBio Pharma Inc. stock pay special dividendsDay Trade & Daily Profit Focused Screening - newser.com
BridgeBio Pharma, Inc. (BBIO) Stock Forecasts - Yahoo! Finance Canada
CapEx per share of BridgeBio Pharma, Inc. – MIL:1BBIO - TradingView
BridgeBio Pharma: A High-Stakes Biotech Investment - AD HOC NEWS
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ceribell, Inc. (CBLL), American Well (AMWL) and BridgeBio Pharma (BBIO) - The Globe and Mail
How BridgeBio Pharma Inc. (2CL) stock reacts to fiscal policiesWeekly Trend Recap & Reliable Price Breakout Signals - newser.com
Why retail investors favor BridgeBio Pharma Inc. stockJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Real time alert setup for BridgeBio Pharma Inc. performance2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Is BridgeBio Pharma Inc. stock a buy in volatile markets2025 Analyst Calls & Free Weekly Chart Analysis and Trade Guides - fcp.pa.gov.br
BridgeBio Pharma Inc (BBIO) Stock Price, Trades & News - GuruFocus
13,856 Shares in BridgeBio Pharma, Inc. $BBIO Purchased by Bryce Point Capital LLC - MarketBeat
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.43%
0.07%
자본화:
|
볼륨(24시간):